A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient setting
| Autor: | Michael Cullen, Carol L. Brown, Daniel Swinson, Syed A. Hussain, D. R. Peake, A. Wills, Daniel Rea, A. D. Chetiyawardana, A. El-Modir, C. Draycott, P. Riley, Daniel H. Palmer |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Cancer Research
medicine.medical_specialty Chemotherapy Performance status business.industry medicine.drug_class medicine.medical_treatment Urology Renal function General Medicine medicine.disease Antimetabolite Gemcitabine Carboplatin Surgery chemistry.chemical_compound Oncology chemistry medicine Lung cancer business Survival rate medicine.drug |
| Zdroj: | Oncology Reports. |
| ISSN: | 1791-2431 1021-335X |
| Popis: | In response to increasing pressure on inpatient services and a meta-analysis indicating that cisplatin (C) is superior to carboplatin, we report a phase II trial of gemcitabine (G) and split-dose C in advanced non-small cell lung cancer (NSCLC) in an outpatient setting. Patients with stage IIIB/IV NSCLC received: G/C 1250/40 mg/m 2 ; G and C were given on day (d) 1 and d8 in a 2 Id cycle. Patients with performance status 0-2, adequate bone marrow function and calculated glomerular filtration rate (GFR) >50 ml/min were eligible. Forty-two patients were enrolled: 25 male; median age 62 (range 37-78) years. There were 26 patients (62%) with stage IV disease. One hundred and thirty-eight cycles of chemotherapy were delivered. Chemotherapy was well tolerated, allowing maintenance of planned dose intensity (DI) with mean dose delivered of 780.1 mg/m 2 (93%) and 25.6 mg/m 2 (96%) for G and C, respectively. The overall response rate was 43%. Median survival was 12.5 months with a median follow-up of 13.5 months. One year survival rate was 51%. G plus C both given on dl and d8 (q21d) is a very active, well tolerated and convenient outpatient schedule, which maintains DI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|